Following Takeda's multibillion-dollar acquisition of cancer drugmaker Ariad Pharmaceuticals, Array Biopharma, Seattle Genetics, and Exelixis could be the next to be bought.
Why AbbVie, Amgen, and Baxter beat Gilead Sciences on some key criteria for investors.
Gilead Sciences' capital return program is doing little to bulk up the share price, and that suggests it's time for the company to get serious about acquisitions.
Looking for cheap biotech stocks you can buy now? These three may be bargains.
Drug development is a tough business. Here's a closer look at seven of the biggest biotech flops of the year.
Shares collapsed after the company announced that it will discontinue development of some of its most promising product candidates.
The Soros Fund showed a healthy appetite for biotech stocks in Q3 -- ignoring the political risk.
Our team of healthcare experts thinks that these three biotech stocks are great choices for beginners.
Arrowhead's stock cratered after the announcement of an FDA clinical hold. Can the biotech make a comeback?
An attractively high dividend rate may have AbbVie on income investors' radar, but there are a few things investors should know about this company before they dive in and buy the stock for its dividend payout.